GlassScriptPhysician profile
Jeremiah H Tyson
NPI 1336382548
$512.72
in general payments reported to CMS, 2019-2025
15 companies · $17.04 in 2025
The $17.04 reported for 2025 was less than what a typical Emergency Medicine provider received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $210 · 2023: $286 · 2025: $17.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227 · Education: $75.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.31 |
| Education | $75.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $87.48 | 2022 | |
| Glaxosmithkline, LLC. | $82.96 | 2023 | |
| Opko Pharmaceuticals, LLC | $75.85 | 2023 | Rayaldee |
| Sanofi-Aventis U.S. LLC | $65.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.10 | 2022-2023 | |
| Genzyme Corporation | $26.71 | 2023 | |
| Aveo Pharmaceuticals, INC. | $24.03 | 2023 | Fotivda |
| Abbvie INC. | $17.04 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.25 | 2022 | |
| Seagen INC. | $15.73 | 2023 | Adcetris |
| Argenx US, INC. | $15.30 | 2022 | |
| Merck Sharp & Dohme LLC | $14.29 | 2023 | Lynparza, Keytruda |
| Dexcom, INC. | $13.24 | 2023 | Dexcom G6 Transmitter |
| Adc Therapeutics America, INC. | $13.20 | 2023 | |
| Neurocrine Biosciences, INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Tyson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.